Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DUL.DE,853362000.0,117545000,161907000,,-188331000,,-189559000,166051000,181798000,-146160000,-146160000,,-33416000,,,,1228000,220553000,366713000,38755000,-42171000,,-189559000,-189559000,5863476000.0,2656067000.0,853362000.0,121020000.0,3509429000.0,1186000.0,-4975219000.0,1379709000.0,-36081000.0,75477000.0,745767000.0,554648000.0,-36081000.0,708789000.0,2725163000.0,1154315000.0,646587000.0,433151000.0,84358000.0,53079000.0,,168435000,45009000,157024000,250000000,329811000,-27124000,81861000,366060000,1081000,-121856000,22161000,-165000,-3955000,-35311000,-2050000,66923000,-11246000,2170515000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,170.65,1630424159,0.0,170.65,173.9,173.9,89,"ALNYLAM PHARMACE.DL-,0001",GER,REGULAR,0.29659995,0,False,False,0.0,173.9 - 173.9,170.65,167.95,169.6,finmb_2796659,XETRA,"Alnylam Pharmaceuticals, Inc.",USD,26,17,68.42999,0.66943836,102.22 - 176.9,-6.25,-0.035330698,102.22,176.9,1619683200,1635937140,1636372800,-6.263,2,7.895,158.16806,12.481934,0.07891564,131.61345,39.036545,18349481984,21.614946,15,Europe/Berlin,CEST,7200000,1.2,,,176.9,102.22,158.17,131.61,26,17,117.55M,,118.15M,0.64%,96.46%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",-128.96%,-109.35%,-13.65%,-78.71%,687.53M,5.89,112.10%,414.8M,-708.47M,-886.68M,-6.26,,1.9B,15.99,761.07M,89.18,4.91,7.89,-590.99M,-791.18M,Value,02142,Healthcare,1453,10,3,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 551 8200,MA,6,1609372800,1625097600,4,United States,http://www.alnylam.com,86400,7,675 West Kendall Street,617 551 8101,Biotechnology,Henri A. Termeer Square
t-1,DUL.DE,926190000.0,117545000,166623000,,-199275000,,-200291000,166135000,146504000,-186254000,-186254000,,-32515000,,,,1016000,177566000,363820000,31062000,-13021000,,-200291000,-200291000,5747394000.0,2329079000.0,926190000.0,130000000.0,3255269000.0,1173000.0,-4785660000.0,1354649000.0,-36717000.0,83401000.0,379543000.0,494825000.0,-36717000.0,701785000.0,2470083000.0,1329994000.0,610626000.0,191590000.0,73940000.0,45381000.0,,92728000,-94377000,71352000,250000000,51177000,-22714000,46977000,-117041000,-3910000,-235660000,22862000,-4198000,1934000,-10709000,4200000,67635000,-17178000,1975258000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,170.65,1630424159,0.0,170.65,173.9,173.9,89,"ALNYLAM PHARMACE.DL-,0001",GER,REGULAR,0.29659995,0,False,False,0.0,173.9 - 173.9,170.65,167.95,169.6,finmb_2796659,XETRA,"Alnylam Pharmaceuticals, Inc.",USD,26,17,68.42999,0.66943836,102.22 - 176.9,-6.25,-0.035330698,102.22,176.9,1619683200,1635937140,1636372800,-6.263,2,7.895,158.16806,12.481934,0.07891564,131.61345,39.036545,18349481984,21.614946,15,Europe/Berlin,CEST,7200000,1.2,,,176.9,102.22,158.17,131.61,26,17,117.55M,,118.15M,0.64%,96.46%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",-128.96%,-109.35%,-13.65%,-78.71%,687.53M,5.89,112.10%,414.8M,-708.47M,-886.68M,-6.26,,1.9B,15.99,761.07M,89.18,4.91,7.89,-590.99M,-791.18M,Value,02142,Healthcare,1453,10,3,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 551 8200,MA,6,1609372800,1625097600,4,United States,http://www.alnylam.com,86400,7,675 West Kendall Street,617 551 8101,Biotechnology,Henri A. Termeer Square
t-2,DUL.DE,1016247000.0,117545000,150358000,,-243599000,,-243540000,184402000,140538000,-194222000,-194222000,,-28517000,,,,-59000,163562000,357784000,23024000,-49377000,,-243540000,-243540000,5644074000.0,2390814000.0,1016247000.0,197163000.0,3407061000.0,1164000.0,-4585369000.0,1321227000.0,-43622000.0,85770000.0,496580000.0,585270000.0,-43622000.0,706514000.0,2614777000.0,1377815000.0,602413000.0,191278000.0,75202000.0,51966000.0,,-55220000,40127000,-97888000,200000000,217950000,4011000,19025000,-110000,2972000,-123144000,20880000,-21000000,-8464000,-21166000,-1075000,85008000,-21668000,2029507000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,170.65,1630424159,0.0,170.65,173.9,173.9,89,"ALNYLAM PHARMACE.DL-,0001",GER,REGULAR,0.29659995,0,False,False,0.0,173.9 - 173.9,170.65,167.95,169.6,finmb_2796659,XETRA,"Alnylam Pharmaceuticals, Inc.",USD,26,17,68.42999,0.66943836,102.22 - 176.9,-6.25,-0.035330698,102.22,176.9,1619683200,1635937140,1636372800,-6.263,2,7.895,158.16806,12.481934,0.07891564,131.61345,39.036545,18349481984,21.614946,15,Europe/Berlin,CEST,7200000,1.2,,,176.9,102.22,158.17,131.61,26,17,117.55M,,118.15M,0.64%,96.46%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",-128.96%,-109.35%,-13.65%,-78.71%,687.53M,5.89,112.10%,414.8M,-708.47M,-886.68M,-6.26,,1.9B,15.99,761.07M,89.18,4.91,7.89,-590.99M,-791.18M,Value,02142,Healthcare,1453,10,3,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 551 8200,MA,6,1609372800,1625097600,4,United States,http://www.alnylam.com,86400,7,675 West Kendall Street,617 551 8101,Biotechnology,Henri A. Termeer Square
t-3,DUL.DE,1215023000.0,117545000,143527000,,-252452000,,-253291000,185728000,104056000,-225199000,-225199000,,-28731000,,,,839000,125853000,351052000,21797000,-27253000,,-253291000,-253291000,5592884000.0,2092260000.0,1215023000.0,124917000.0,3307283000.0,1161000.0,-4341829000.0,1314757000.0,-37193000.0,62657000.0,496704000.0,480241000.0,-37193000.0,689924000.0,2554702000.0,1337172000.0,579118000.0,,66942000.0,27872000.0,5000.0,2330000,64694000,-10088000,200000000,34147000,4987000,29947000,-84125000,2142000,-110326000,18771000,-21000000,-2784000,-8971000,4200000,66268000,-12418000,2074461000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,170.65,1630424159,0.0,170.65,173.9,173.9,89,"ALNYLAM PHARMACE.DL-,0001",GER,REGULAR,0.29659995,0,False,False,0.0,173.9 - 173.9,170.65,167.95,169.6,finmb_2796659,XETRA,"Alnylam Pharmaceuticals, Inc.",USD,26,17,68.42999,0.66943836,102.22 - 176.9,-6.25,-0.035330698,102.22,176.9,1619683200,1635937140,1636372800,-6.263,2,7.895,158.16806,12.481934,0.07891564,131.61345,39.036545,18349481984,21.614946,15,Europe/Berlin,CEST,7200000,1.2,,,176.9,102.22,158.17,131.61,26,17,117.55M,,118.15M,0.64%,96.46%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Jun 30, 2021",-128.96%,-109.35%,-13.65%,-78.71%,687.53M,5.89,112.10%,414.8M,-708.47M,-886.68M,-6.26,,1.9B,15.99,761.07M,89.18,4.91,7.89,-590.99M,-791.18M,Value,02142,Healthcare,1453,10,3,"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 551 8200,MA,6,1609372800,1625097600,4,United States,http://www.alnylam.com,86400,7,675 West Kendall Street,617 551 8101,Biotechnology,Henri A. Termeer Square
